Acurx Pharmaceuticals Q1 2024 GAAP EPS $(0.28) Misses $(0.24) Estimate
Portfolio Pulse from Benzinga Newsdesk
Acurx Pharmaceuticals (NASDAQ:ACXP) reported a Q1 2024 GAAP EPS of $(0.28), missing the analyst consensus estimate of $(0.24) by 16.67%. This represents a 12% increase in losses compared to the same period last year.
May 15, 2024 | 11:12 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Acurx Pharmaceuticals reported a Q1 2024 GAAP EPS of $(0.28), missing the analyst consensus estimate of $(0.24) by 16.67%. This represents a 12% increase in losses compared to the same period last year.
The reported EPS of $(0.28) missed the analyst estimate of $(0.24) by a significant margin (16.67%), indicating worse-than-expected financial performance. Additionally, the losses increased by 12% compared to the same period last year, which is likely to negatively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100